A Comparison of Cell-Cycle Markers in Skull Base and Sacral Chordomas
- 1 July 2014
- journal article
- research article
- Published by Elsevier BV in World Neurosurgery
- Vol. 82 (1-2), e311-e318
- https://doi.org/10.1016/j.wneu.2013.01.131
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- The Mdm2–p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressorGenes & Development, 2010
- Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathwayBritish Journal of Cancer, 2009
- Proton therapy in chordoma of the base of the skull: a systematic reviewNeurosurgical Review, 2009
- Crystal structure of human CDK4 in complex with a D-type cyclinProceedings of the National Academy of Sciences of the United States of America, 2009
- Frequent deletion of the CDKN2A locus in chordoma: analysis of chromosomal imbalances using array comparative genomic hybridisationBritish Journal of Cancer, 2007
- Analysis of immunohistochemical expression of p53 and the proliferation marker Ki-67 antigen in skull base chordomas: relationships between their expression and prognosisBrain Tumor Pathology, 2007
- Dissection of Protein–Protein Interaction and CDK4 Inhibition in the Oncogenic versus Tumor Suppressing Functions of Gankyrin and P16Journal of Molecular Biology, 2007
- CDK4 Inhibitors and Apoptosis: A Novel Mechanism Requiring Nucleolar Targeting of RelACell Cycle, 2007
- Live or let die: the cell's response to p53Nature Reviews Cancer, 2002
- p53, guardian of the genomeNature, 1992